Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

Abstract

Atezolizumab regimens of 840 mg q2w and 1680 mg q4w are expected to have comparable efficacy and safety as the approved regimen of 1200 mg q3w, supporting their interchangeable use and offering patients greater flexibility.